Coherus BioSciences, Inc.

CHRS · Nasdaq · United States

Share price · CHRS

$0.41-0.93 (-69.41%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.6M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CHRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-14.3%
  2. 10 Nov 2026-21.6%
  3. 29 Oct 2026-22.6%
  4. 18 Sep 2026+9.8%
  5. 18 Aug 2026+16.5%
  6. 6 Aug 2026-12.8%
  7. 12 May 2026-12.3%
  8. 11 May 2026+11.4%
  9. 13 Feb 2026-19.9%

    Nothing announced by CHRS that day or the session before.

  10. 23 Jan 2026+29.6%

Share of unusual movement by asset

For each asset, the share of CHRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerBiliary Tract CancerNasopharyngeal Carcinoma
Cholangiocarcinoma

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
ToripalimabPhase 2/3Hepatocellular Carcinoma
Est. primary completion 2026-12-31 · NCT03859128 · CT.gov ↗
What to watch
ToripalimabPhase 3Advanced Hepatocellular Carcinoma (HCC)
Est. primary completion 2026-12-31 · NCT04523493 · CT.gov ↗
What to watch
2027 (8)
March 2027 (1)
ToripalimabPhase 3Gastric or Esophagogastric Junction Adenocarcinoma
Est. primary completion 2027-03-31 · NCT05180734 · CT.gov ↗
What to watch
May 2027 (2)
ToripalimabPhase 3Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-05-12 · NCT04848753 · CT.gov ↗
What to watch
ToripalimabPhase 3Intrahepatic Cholangiocarcinoma
Est. primary completion 2027-05-31 · NCT05342194 · CT.gov ↗
What to watch
June 2027 (1)
ToripalimabPhase 2Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-30 · NCT07484724 · CT.gov ↗
What to watch
July 2027 (1)
ToripalimabPhase 3Limited-stage Small Cell Lung Cancer (LS-SCLC)
Est. primary completion 2027-07-31 · NCT06095583 · CT.gov ↗
What to watch
November 2027 (2)
ToripalimabPhase 2Advanced Lung Cancer
Est. primary completion 2027-11-30 · NCT07309276 · CT.gov ↗
What to watch
ToripalimabPhase 2Advanced Malignant Solid Tumors
Est. primary completion 2027-11-30 · NCT07480733 · CT.gov ↗
What to watch
December 2027 (1)
ToripalimabPhase 2Triple-negative Breast Cancer
Est. primary completion 2027-12-31 · NCT07876557 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Filing acceptedToripalimabNMPA accepts sNDA for perioperative toripalimab plus chemotherapy in stage II-III NSCLC
CN, NMPA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$14M$23M$54M+ $30M short-term inv.$39M-$34M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$14M$21M$83M+ $22M short-term inv.$21M-$62M operating cash flowreport ↗
2026-Q1$12M$22M$115M+ $52M short-term inv.$38M-$58M operating cash flowreport ↗
2025-Q3$12M$27M$104M+ $88M short-term inv.$36M-$46M operating cash flowreport ↗
2025-Q2$10M$26M$217M+ $21M short-term inv.—-$47M operating cash flowreport ↗
2025-Q1$7.6M$24M$83M$57M-$26M operating cash flowreport ↗
2024-Q3$71M$22M$98M$11M-$62M operating cash flowreport ↗
2024-Q2$65M$22M$160M$13M$60M operating cash flowreport ↗
2024-Q1$77M$28M$260M—-$47M operating cash flowreport ↗
2023-Q3$75M$26M$81M+ $51M short-term inv.$40M-$54M operating cash flowreport ↗
2023-Q2$59M$23M$73M+ $72M short-term inv.$43M-$39M operating cash flowreport ↗
2023-Q1$32M$34M$17M+ $112M short-term inv.$76M-$69M operating cash flowreport ↗
2022-Q3$45M$46M$287M$87M-$37M operating cash flowreport ↗
2022-Q2$60M$42M$276M$50M-$50M operating cash flowreport ↗
2022-Q1$60M$83M$326M$96M-$54M operating cash flowreport ↗
2021-Q3$83M$54M$361M+ $108M short-term inv.$39M$14M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$42M$109M$89M+ $83M short-term inv.—-$139M operating cash flowreport ↗

In fiscal year 2025, Coherus reported revenue of $42.17M, down 84.2% YoY, and R&D expense of $108.89M, up 16.7% YoY. Cash and cash equivalents were $89.12M at year-end, with total cash, cash equivalents and marketable securities of $172.1M. The company reported net income of $168.02M for 2025, including a $351.1M contribution from discontinued operations; net loss from continuing operations was $183.1M, or $(1.56) per diluted share, versus $215.4M, or $(1.88) per diluted share, in 2024.

LOQTORZI net revenue more than doubled to $40.8M in 2025 from $19.1M in 2024. The company reduced secured and convertible debt by 90% from $480M to $38.8M over 2024-2025, and raised approximately $7.9M in net proceeds from an October 2025 equity sale and approximately $47.0M from a February 2026 public offering. Clinical updates included six-year overall survival data from the Phase 3 JUPITER-02 trial presented at ESMO Asia, ongoing tagmokitug combination studies with initial data readouts expected in mid-2026 and 2H 2026, an ongoing randomized Phase 2 casdozokitug/toripalimab/bevacizumab trial in 1L uHCC with a first readout expected in mid-2026, and a planned Phase 1b study of tagmokitug with J&J’s pasritamig in mCRPC expected to start in 2H 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$267M$93M$126M—-$20M operating cash flowreport ↗
2023-FY$257M$109M$103M+ $15M short-term inv.$59M-$175M operating cash flowreport ↗
2022-FY$211M$199M$64M+ $128M short-term inv.$73M-$241M operating cash flowreport ↗
2021-FY$327M$363M$418M$72M-$37M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-05Newton Charles W. · directorAward / grant30,000——Form 4
2026-06-05Wahlstrom Mats · directorAward / grant30,000——Form 4
2026-06-05O'Donnell-Tormey Jill · directorAward / grant30,000——Form 4
2026-06-05Ryan Michael Lee · directorAward / grant30,000——Form 4
2026-06-05Newcomer Lee Nisley · directorAward / grant30,000——Form 4
2026-06-05Karachun Rita A · directorAward / grant30,000——Form 4
2026-06-05Satvat Ali J. · directorAward / grant30,000——Form 4
2026-06-05Newton Charles W. · directorAward / grant (derivative)60,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 156 reporting institutions held 59.1M shares ($95.5M, 38.3% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.10,365,074$17.5M
2VANGUARD CAPITAL MANAGEMENT LLC5,452,762$9.2M
3SAMSARA BIOCAPITAL, LLC3,428,571$5.8M
4GEODE CAPITAL MANAGEMENT, LLC3,121,578$5.3M
5Kohlberg Kravis Roberts & Co. L.P.3,036,076$5.1M
6STATE STREET CORP2,325,859$3.9M
7TWO SIGMA INVESTMENTS, LP2,302,001$3.9M
8Alyeska Investment Group, L.P.2,250,000$3.8M
9CM Management, LLC2,100,000$3.5M
10TANG CAPITAL MANAGEMENT LLC1,886,748$3.2M
11Hudson Bay Capital Management LP1,704,980$2.9M
12PANAGORA ASSET MANAGEMENT INC1,459,310$2.5M
13Propel Bio Management, LLC1,420,550$2.4M
14AQR CAPITAL MANAGEMENT LLC1,206,046$2.0M
15CHARLES SCHWAB INVESTMENT MANAGEMENT INC1,155,901$2.0M